Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers.
Abstract
Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers.
Methods: IRS1 rs1801123, rs1330645, and rs1801278 were genotyped in samples from 36 centers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analyzed by a retrospective cohort approach modeling the associations with breast and ovarian cancer risks simultaneously. Analyses were stratified by BRCA1 and BRCA2 status and mutation class in BRCA1 carriers.
Results: Rs1801278 (Gly972Arg) was associated with ovarian cancer risk for both BRCA1 (HR, 1.43; 95% confidence interval (CI), 1.06-1.92; P ¼ 0.019) and BRCA2 mutation carriers (HR, 2.21; 95% CI, 1.39-3.52, P ¼ 0.0008). For BRCA1 mutation carriers, the breast cancer risk was higher in carriers with class II mutations than class I mutations (class II HR, 1.86; 95% CI, 1.28-2.70; class I HR, 0.86; 95%CI, 0.69-1.09; P difference , 0.0006). Rs13306465 was associated with ovarian cancer risk in BRCA1 class II mutation carriers (HR, 2.42; P ¼ 0.03).
Conclusion: The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers and breast cancer risk in BRCA1 class II mutation carriers.
Impact: These findings may prove useful for risk prediction for breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 21 (8) ; 1362-70. Ó2012 AACR.
Introduction
Women who carry mutations in BRCA1 or BRCA2 are at a substantially increased risk of developing breast and/or ovarian cancers. Lifetime risks for breast cancer range from 40% to 87% and for ovarian cancer from 11% to 68% (1, 2) . In addition to variability in the incidence of breast and ovarian cancers, there is also variability in age at diagnosis and type of cancer in the index case (proband; ref. 1) even among women who carry the same BRCA mutation (3) and among women in the same family (4). These observations suggest that cancer risk in mutation carriers is modified by other genetic and/or environmental factors.
Insulin receptor substrate 1 (IRS1) is a docking protein for both the insulin-like growth factor receptor 1 (IGF1R) and the insulin receptor (IR) and as such is central to a network of intracellular signaling molecules (5) . The IGF pathway plays crucial roles in regulating cell proliferation, differentiation, and apoptosis through downstream signaling in the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways (6) . It is a key factor in the development and progression of breast cancer (reviewed in refs. 7-9) and in ovarian cancer (10) . The insulin signaling pathway is primarily involved in regulation of metabolism, and a growing body of data support its significant roles in cancer initiation and progression (5, 11) .
We previously reported significant associations between a haplotype and genetic variants rs1801123 and rs1330645 in IRS1 and risk of breast cancer in women carrying BRCA1 with a similar, but nonsignificant haplotype HR observed in women carrying BRCA2 mutations (12) . The risk of developing ovarian cancer was not investigated. The objective of this study was to investigate whether these 3 single-nucleotide polymorphisms (SNPs) modify risk of developing ovarian cancer and breast cancer in a large set of BRCA1 and BRCA2 mutation carriers within the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Materials and Methods
Subjects: BRCA1 and BRCA2 mutation carriers Carriers of pathogenic mutations in BRCA1 and BRCA2 were from one of 36 centers from North America, Europe, The Mediterranean, and Australia participating in CIMBA (13) . The participants were enrolled under Institutional Review Board (IRB)-approved protocols at the respective institutions, and all signed informed consent. Inclusion criteria for this analysis were female carriers of pathogenic BRCA1 or BRCA2 mutations who were 18 years or older at recruitment and were of self-reported non-Hispanic white Caucasian ancestry. Information collected included year of birth, mutation type including nucleotide position and base change, age at last follow-up, age at breast and/or ovarian cancer diagnosis, and age or date at bilateral prophylactic mastectomy or oophorectomy. Characteristics of the mutations carriers are shown in the Supplementary Table.
Genotyping
The 3 SNPs, rs1801123, rs1801278, and rs1330645, were genotyped either by 5 0 exonuclease TaqMan assays (Applied Biosystems) run on an ABI9700 detection system or single-base primer extension as part of a Sequenom iPLEX Gold assay run on a Sequenom MassARRAY system (Table 1) . To ensure consistency in genotyping, genotyping centers were required to adhere to strict genotyping quality control criteria. We included a minimum of 2% of the samples in duplicate, no template controls in every plate, and a random mixture of affected and unaffected carriers. Samples that failed for 2 or more of the SNPs genotyped (among those analyzed in that genotyping round) were excluded from the analysis. The genotype data for a given SNP and a given study were included in the analysis only if the call rate was more than 95% after samples that failed at multiple SNPs had been excluded. The concordance between duplicates had to be at least 98%. To assess the accuracy of genotyping across genotyping centers, all centers genotyped 95 DNA samples from a standard test plate (Coriell Institute, Camden, NJ) for all SNPs. If the genotyping was inconsistent for more than one sample in the test plate, the study was excluded from the analysis of that SNP. As an additional genotyping quality control check, we also evaluated the deviation from Hardy-Weinberg equilibrium (HWE) for unrelated subjects separately for each SNP and study. Studies with a HWE P value of less than 0.005 were excluded from the analysis. If HWE P values were in the range of 0.005to 0.05, we examined the genotyping cluster plots; none revealed any unusual patterns and these studies were therefore included in all the analyses. Within CIMBA, SNPs were selected to be genotyped in the full panel of carriers at the time, or in a smaller set of carriers that were genotyped at the Queensland Institute of Medical Research (QIMR, Royal Brisbane Hospital, Brisbane, Australia). Thus, based on our previous result, SNP rs1801123 was selected to be genotyped in all available BRCA1 and BRCA2 mutation carriers, whereas rs13306465 and rs1801278 were genotyped only in DNA stored at QIMR (Table 1) .
Statistical analysis
Mutation carriers in CIMBA are mainly ascertained through ongoing genetic testing programs primarily aimed at screening young affected individuals for BRCA1 and BRCA2 mutations. Therefore, mutation carriers in our sample are not randomly sampled with respect to their disease phenotype. To account for sampling, data were analyzed within a retrospective cohort framework by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes (14) . To obtain estimates of the risk ratios for both breast and ovarian cancers, and given the prior evidence of variants in IRS1 and association with breast cancer risk, analyses were conducted within a competing risk model in which breast and ovarian cancer risks were modeled simultaneously (15) . This has been shown to yield valid tests of association for both diseases and to provide unbiased estimates of the risk ratios (15) . In this model, each individual was assumed to be at the risk of developing either breast or ovarian cancer, and the probabilities of developing each disease were assumed to be independent, conditional on the underlying genotype. Individuals were followed up to the age of the first breast or ovarian cancer diagnosis and were considered to have developed the corresponding disease. No follow-up was considered after the first cancer diagnosis. Individuals were censored for breast cancer at the age of bilateral prophylactic mastectomy and for ovarian cancer at the age of bilateral oophorectomy and, in such circumstances, were assumed to be unaffected for the corresponding disease. The remaining individuals were censored at the age at last observation and were assumed to be unaffected for both diseases. Individuals who were diagnosed with both breast and ovarian cancers at the same age were treated as ovarian cancer cases. Models were implemented in the pedigree analysis software MENDEL (16) . Each woman was considered to be at risk of developing either breast or ovarian cancer by assuming that the probabilities of developing each disease were independent, conditional on the underlying genotype. Women with cancer were followed up to the age of the first breast or ovarian cancer diagnosis and were considered affected with that cancer. No follow-up was considered after the first cancer diagnosis. Individuals were censored for breast cancer at the age of bilateral prophylactic mastectomy and for ovarian cancer at the age of bilateral oophorectomy, and were assumed to be unaffected for the corresponding cancer. The remaining individuals were censored at the age at last observation and were assumed to be unaffected for both cancers. Breast and ovarian cancer incidences were assumed to depend on the underlying SNP genotype through a Cox proportional hazards model. The models were parameterized in terms of the per-allele HR for effect of the minor allele at each SNP. All analyses used calendar period-and cohort-specific incidences for BRCA1 and BRCA2 mutation carriers and were stratified by study center and country of residence. A robust variance estimation approach was used to allow for nonindependence among related carriers (17, 18) . Tests for difference in the log-HR estimates for class I and class II mutations were based on a test statistic for the equality of 2 normally distributed random variables.
Results
The centers, number of samples from each center, and genotyping platforms used are shown in Table 1 . The number of mutation carriers by censoring event is shown in Table 2 . SNP rs1801278 (Gly972Arg) was significantly associated with ovarian cancer risk in both BRCA1 and BRCA2 mutation carriers (BRCA1: HR, 1.43; 95% CI, 1.06-1.92; P, 0.019; BRCA2: HR, 2.21; 95% CI, 1.39-3.52; P 0.0008). There was no association of this SNP with breast cancer risk within the overall unstratified sets of BRCA1 and BRCA2 mutation carriers. SNPs rs13306465 and rs1801123 were not associated with breast or ovarian cancers for either BRCA1 or BRCA2 mutation carriers.
For BRCA1, we also evaluated the SNP associations by mutation type based on the predicted functional consequence (described in detail previously in ref. 19 ). There were too few BRCA2 carriers to stratify by mutation type. Class I mutations are predicted to result in a reduced transcript or protein level due to nonsense-mediated RNA decay, whereas class II mutations are likely to generate stable protein with potential residual or dominant-negative function. None of the SNPs were significantly associated with risk of developing breast or ovarian cancers among BRCA1 class I mutation carriers. However, among class II mutation carriers, there was a significant association of rs1801278 with the risk of developing both ovarian cancer (HR, 2.17; 95% CI, 1.21-3.90; P ¼ 0.009) and breast cancer (HR, 1.86; 95% CI, 1.28-2.70; P ¼ 0.001). The HR estimates for class II mutations were significantly higher than those for class I mutations, for breast cancer (breast cancer class II HR, 1.86; 95% CI, 1.28-2.70; class I HR, 0.86, 95% CI, 0.69-1.09; P for difference between class I and class II mutations ¼ 0.0006). The difference was not significant by mutation class for risk of ovarian cancer (ovarian cancer class II HR, 2.17; 95% CI, 1.21-3.90; class I HR, 1.33; 95% CI, 0.95-1.86; P for difference between class I and class II mutations ¼ 0.15). There was also evidence of an association between rs13306465 and risk of developing ovarian cancer for BRCA1 class II mutation carriers (HR, 2.42; 95% CI, 1.06-5.56; P ¼ 0.037).
Discussion
Previously, we identified a significant association of risk of breast cancer in BRCA1 mutation carriers and a rare haplotype composed of the 3 SNPs studied here (HR, 1.43; 95% CI, 1.06-1.95; P ¼ 0.021; ref. 12). A similar, but nonsignificant HR of 1.52 (95% CI, 0.99-2.32; P, 0.055) was observed in BRCA2 carriers. For rs13306465 and rs1801123, individuals carrying at least one variant allele experienced a 44% (HR, 1.44; 95% CI, 1.07-1.94) and 37% (HR, 1.37; 95% CI, 1.11-1.69) higher risk of breast cancer relative to wild-type carriers, respectively. There was no individual association of the rs1801278 (Gly972Arg) variant and breast cancer risk. In this current study, we expanded these analyses and investigated, for the first time, whether these 3 IRS1 SNPs were associated with ovarian cancer risk, as well as with breast cancer risk in this larger cohort of BRCA1 and BRCA2 mutation carriers.
We found that rs1801278 (Gly972Arg) in IRS1 was significantly associated with ovarian cancer risk for both BRCA1 and BRCA2 mutation carriers. In analyses stratified by mutation function, the ovarian cancer risk for BRCA1 mutation carriers was especially pronounced in women who carried mutations predicted to retain residual BRCA1 function (class II mutations; HR, 2.2; 95% CI, 1.2-3.9; P ¼ 0.009). There was also a significant association of this SNP with breast cancer risk (HR ¼ 1.86), but limited to women who carried class II mutations, with no discernable effect on breast cancer risk in women who carried class I mutations. There was marginal evidence of association between rs13306465 and ovarian cancer risk for BRCA1 class II mutation carriers. The previous statistically significant associations of rs13306465 and rs1801123 and breast cancer risk in BRCA1 mutation carriers were not observed in this larger set of mutation carriers. Additional carriers within CIMBA should be tested to further refine the estimates of risk for the IRS1 Gly972Arg mutation.
There have been a limited number of epidemiologic studies of the association of sporadic breast cancer risk and genetic variation in IRS1 (20, 21) . The rs1801278 was associated with postmenopausal breast cancer in Hispanic, but not non-Hispanic whites in the Southwest US (21) . Two other IRS1 SNPs investigated in the Cancer Prevention II study were not associated with risk in postmenopausal breast cancer (20) . There have been no reports of studies investigating the association of SNPs in IRS1 and ovarian cancer. From a meta-analysis of 11 studies, rs1801278 has been associated with an increased risk of developing polycystic ovary syndrome (22) .
Gly972 (rs1801278) in the IRS1 protein is located between 2 tyrosine phosphorylation sites involved in binding downstream effectors including the regulatory p85 subunit of PI3K and Grb2 (23) . The Arg972 variant results in altered function of the IRS1 protein, leading to a decreased ability of IRS1 to bind the p85 subunit of PI3K in vitro. In 2 studies of 32D mouse myeloid progenitor cells lacking IRS-1 (32D-IR cells), the Gly972Arg variant resulted in decreased binding to the p85 subunit of PI3K by 25% and 42% and decreased PI3K activity by 36% and 39%, respectively (24, 25) . Studies of the insulin signaling pathway in both cultured cells and in transgenic mice have shown that this variant is associated with impaired insulin-stimulated signaling, likely contributing to insulin resistance (24, 26, 27) . Interestingly, epidemiologic data have long suggested that insulin resistance might be a breast cancer risk factor, but study results have been inconsistent. In a 2007 review of all the available epidemiology studies, Xue and Michels concluded that having type II diabetes was modestly associated with the risk of breast cancer (28) . IRS1 is partially regulated through a negative feedback loop in the downstream PI3K signaling pathway. Insulin activates c-jun-NH 2 -kinase (JNK), extracellular signalregulated kinase (ERK), protein kinase C (PKC), and mTOR, which then can induce the phosphorylation of IRS1 at specific sites, inhibiting its ability for downstream signaling (29) . In experiments in MCF-7 breast cancer cells, IGF-1 was shown to induce IRS-1 degradation, which could be blocked by PI3K inhibitors, suggesting a direct negative-feedback mechanism of PI3K that degrades IRS-1 and thus blocks further IGF signaling (29) . It is possible that with decreased PI3K binding, less IRS-1 is degraded resulting in longer signaling through both PI3K and RAS-ERK pathways. Alternatively, decreased binding of IRS-1 to PI3K may allow for activation of the pathway by other ligands that are not regulated through a negative-feedback mechanism, thereby increasing downstream signaling (30) .
BRCA1 interacts directly with the IRS-1 promoter to inhibit its activity (31) , and with induction of BRCA1, there was a 2-to 3-fold decrease of IRS-1 mRNA and protein levels, as well as a decrease in the phosphorylation level of AKT, a downstream target of IRS-1 (31). In the current study, we found that Gly972Arg conferred a higher risk of ovarian cancer for BRCA1 mutation carriers with class II mutations (predicted to produce a stable aberrant protein) compared with class I mutations (predicted to undergo nonsense-mediated decay), and modified breast cancer risk only in class II BRCA1 carriers. As class 1 BRCA1 mutations result in loss of the BRCA1 protein, this would result in failure to inhibit IRS-1 levels such that the levels of IRS-1 may be elevated in women carrying class I mutations. From this, it follows that the effects of the Gly972Arg may be attenuated in class I mutation carriers because of the increased levels of IRS1, and that the reduction in signaling from the Arg972 variant in IRS-1 only plays a role in BRCA1 class II and BRCA2 carriers, for whom stable BRCA1 protein is still suppressing IRS-1 expression. To test this hypothesis, future experiments can be carried out to evaluate the effects of the IRS-1 Gly972Arg on PI3K signaling in carriers of both class I and II BRCA1 mutations. It is not known whether the effect we are observing is due to signaling through insulin or through IGF or through both.
In summary, the IRS1 Gly972Arg SNP, known to affect both IGF and insulin signaling, significantly modifies risk of developing ovarian cancer in both BRCA1 and BRCA2 mutation carriers with more than a 2-fold increased risk, and of developing breast cancer in BRCA1 class II mutation carriers with an almost 2-fold increased risk. These findings may prove useful for risk prediction for breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers. Given the known interactions between IRS1 and BRCA1, studies to investigate response to therapies targeted to the PI3K-AKT downstream signaling pathways in BRCA-related breast and ovarian cancers may have merit. The Editor-in-Chief of Cancer Epidemiology, Biomarkers and Prevention is an author of this article. In keeping with the AACR's Editorial Policy, the paper was peer reviewed and a member of the AACR's Publications Committee rendered the decision concerning acceptability. 
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